[1] Kitada M, Kanasaki K, Koya D. Clinical therapeutic strate-gies for early stage of diabetic kidney disease[J]. World J Diabetes, 2014, 5(3):342-356. [2] 齐敏友, 杨钧杰, 周斌, 等. 熊果酸对糖尿病小鼠肾病的保护作用及机制研究[J]. 中国应用生理学杂志, 2014, 30(5):445-448. [3] Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes[J]. Exp Gerontol, 2011, 46(4):217-224. [4] Skov J. Effects of GLP-1in the kidney[J]. Rev Endocr Metab Disord, 2014, 15(3):197-207. [5] Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight[J]. Endocrinology, 2005, 146(4):2069-2076. [6] Panchapakesan U, Mather A, Pollock C. Role of GLP-1and DPP-4in diabetic nephropathy and cardiovascular disease[J]. Clin Sci (Lond), 2013, 124(1):17-26. [7] 李颖萌, 范雪梅, 王义明, 等. 葛根芩连汤对2型糖尿病大鼠的治疗作用及其机制探讨[J]. 药学学报, 2013, 48(9):1415-1421. [8] Nielsen LL, Young AA, Parkes DG. Pharmacology of exe-natide (synthetic exendin-4):a potential therapeutic for im-proved glycemic control of type 2diabetes[J]. Regul Pept, 2004, 117(2):77-88. [9] Xu WW, Guan MP, Zheng ZJ, et al. Exendin-4alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway[J]. Cell Physiol Biochem, 2014, 33(2):423-432. [10] Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy:possible mech-anism and therapeutic potential[J]. Kidney Int, 2014, 85(3):579-589. [11] Tesch GH, Lim AK. Recent insights into diabetic renal in-jury from the db/db mouse model of type 2diabetic nephropa-thy[J]. Am J Physiol Renal Physiol, 2011, 300(2):F301-310. [12] 杨锐, 刘小粉, 马善峰, 等. 硫化氢对1型糖尿病大鼠肾脏的保护作用[J]. 中国应用生理学杂志, 2016, 32(2):181-184. |